Psilocybin therapy
Psilocybin-assisted therapy for depression and other conditions.
Papers per year
Each bar is 12 months; the last one ends 17 Oct 2026. New trials in the same years: 47, 32, 54, 60, 53.
New guidelines and consensus this year
- Challenges with clinical trial participants in studies with classical psychedelics: A position statement from the National Network of Depression Centers' task group on psychedelics and related compoundsJ Psychopharmacol2026 May
- Considerations and cautions for the integration of psilocybin into routine clinical care: a consensus statement from the US National Network of Depression Centers' Task Group on Psychedelics and Related CompoundsEClinicalMedicine2025 Nov
All papers from the last 12 months
643 papers (18 Oct 2025 – 17 Oct 2026), newest first. Loading the full list…
- A response to the letter to editor: Breaking the chains of depression: A systematic review and meta-analysis of psilocybin therapyJ Affect Disord2026 Dec 15PMID 42686072
- Correspondence: "Breaking the chains of depression: A systematic review and meta-analysis of psilocybin therapy"J Affect Disord2026 Dec 1PMID 42562064
- Subacute and long-term changes in cognitive functioning after administration of classic psychedelics, MDMA and ketamine: A systematic review of clinical and preclinical evidenceNeurosci Biobehav Rev2026 NovPMID 42600962Systematic review
- Impact of Psilocybin on Motor Function in Healthy Participants: A Phase 1, Randomised, Triple-Blind, Dose-Finding StudyCNS Drugs2026 NovPMID 42566154RCT
- Safety and Efficacy of Psilocybin During Anticancer Treatment: A Phase II Trial Secondary AnalysisJ Pain Symptom Manage2026 NovPMID 42546985
- α(2)-Adrenergic receptor modulates 5-HT(2A)-mediated behavioral effects of MDMA and psilocybin in miceMol Psychiatry2026 NovPMID 42414551
- Pupil-DLC: An open-source deep learning pipeline for scalable, marker-less tracking of pupil dynamics across conscious and unconscious statesJ Neurosci Methods2026 NovPMID 42401399
- Novel approaches in depression treatment: from rapid-acting antidepressants to personalized interventionsMol Psychiatry2026 NovPMID 42350785Review
- Changes in anxiety, quality of life, and functioning following psilocybin-assisted therapy in veterans with treatment-resistant depressionJ Affect Disord2026 Nov 1PMID 42248535Clinical trial
- French psychiatric caregivers' perceptions of psychedelics: A national surveyEncephale2026 Oct 16PMID 42888158
More psychiatry trends
All specialties →ADHD in adults
Diagnosis and treatment of ADHD in adults.
Loneliness and health
Loneliness and social isolation as risk factors.
Gut microbiome and mental health
Links between the gut microbiome and depression or anxiety.
Brain stimulation for depression
Transcranial magnetic stimulation, including accelerated theta-burst protocols, for depression.
Key point: Connectivity- or frequency- and connectivity-individualized accelerated iTBS failed to yield significant antidepressant benefits over sham stimulation in treatment-resistant depression.
MDMA-assisted therapy
MDMA combined with psychotherapy, mainly studied in PTSD.
Ketamine and esketamine for depression
Ketamine and esketamine for treatment-resistant depression.
Too many papers to read?
PubDaily picks the ones that matter in your specialty and summarises them, about 10 minutes a week.
How these numbers are counted
PubMed query, searched in titles and abstracts by publication date:
psilocybin[tiab]Trials: ClinicalTrials.gov studies first submitted in each 12-month window that match the same terms. A query can miss synonyms or catch unrelated papers, so treat counts as approximate.